Investigational drug · Phase 3
Casdatifan
Also called: AB521
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma (RCC).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
12
Any phase or sponsor naming "Casdatifan"
First trial start
2025
Sep 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Casdatifan", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Metastatic Clear Cell Renal Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma (RCC)
- Carcinoma, Renal Cell
- Advanced Renal Cell Carcinoma
- Renal Cancer
- Renal Neoplasm
- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Clear-cell Metastatic Renal Cell Carcinoma
Approved drugs for the same conditions: Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Casdatifan" as an intervention, largest first.
- Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaPivotal-lookingRecruiting
Arcus Biosciences, Inc.Industry
NCT07011719 · 720 participants (planned) · Start Sep 8, 2025 · Primary completion Apr 2028
Drug: Casdatifan; Cabozantinib and 1 more · For: Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma
Sites: Gilbert, Arizona; Goodyear, Arizona; Phoenix, Arizona · 191 sites in all
Arcus Biosciences, Inc.Industry
NCT05536141 · 512 participants (planned) · Start Oct 26, 2022 · Primary completion Mar 2029
Drug: Casdatifan; Cabozantinib and 5 more · For: Clear Cell Renal Cell Carcinoma; Solid Tumors
Sites: Birmingham, Alabama; San Diego, California; Santa Monica, California · 25 sites in all
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07293351 · 474 participants (planned) · Start Mar 26, 2026 · Primary completion Nov 28, 2029
Drug: Pumitamig; Ipilimumab and 2 more · For: Advanced Renal Cell Carcinoma (RCC)
Sites: Palo Alto, California; New Haven, Connecticut; Washington D.C., District of Columbia · 95 sites in all
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07227415 · 224 participants (planned) · Start Feb 10, 2026 · Primary completion Nov 2, 2027
Drug: PF-08634404; Ipilimumab and 2 more · For: Carcinoma, Renal Cell; Advanced Renal Cell Carcinoma; Renal Cancer and 10 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fayetteville, Arkansas · 183 sites in all
Arcus Biosciences, Inc.Industry
NCT05117554 · 70 participants · Start Nov 9, 2021 · Primary completion Feb 17, 2023
Drug: casdatifan; Placebo and 1 more · For: Healthy Participants
Sites: Groningen, Netherlands
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07397611 · 32 participants (planned) · Start Mar 9, 2026 · Primary completion Jan 31, 2028
Drug: Casdatifan; Zimberelimab · For: Renal Cell Carcinoma; Kidney Cancer; Kidney Neoplasm and 1 more
Sites: Boston, Massachusetts · 3 sites in all
- A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult VolunteersCompleted
Arcus Biosciences, Inc.Industry
NCT05999513 · 24 participants · Start Aug 21, 2023 · Primary completion Oct 31, 2023
Drug: casdatifan · For: Healthy Participants
Sites: Lincoln, Nebraska
Arcus Biosciences, Inc.Industry
NCT07641881 · 24 participants · Start May 29, 2026 · Primary completion Jul 3, 2026
Drug: Casdatifan · For: Healthy Participants
Sites: Tempe, Arizona
Arcus Biosciences, Inc.Industry
NCT07751250 · 16 participants (planned) · Start Aug 14, 2026 · Primary completion May 2027
Drug: Casdatifan · For: Healthy Participants; Hepatic Impairment
Sites: San Antonio, Texas
Arcus Biosciences, Inc.Industry
NCT06919991 · 14 participants · Start May 2, 2025 · Primary completion Oct 18, 2025
Drug: Casdatifan; Itraconazole and 1 more · For: Healthy Participants
Sites: Tempe, Arizona
Newest research
PubMed records naming it or its code names, newest first.
- Formal Synthesis of HIF-2α Inhibitor Casdatifan (AB521): Stereospecific Copper(I)-Mediated Ring Opening of Chiral 2-Aryl-cyclopropane-1,1-dicarboxylate with Aryl Grignard Reagents.
Pang H, Yin X, Song ZJ, et al. · J Org Chem 2026
- Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Choueiri TK, Merchán J, Patnaik A, et al. · Nature 2026
- Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Choueiri TK, Merchán J, Patnaik A, et al. · Nature 2026
- Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α.
Mailyan AK, Mata G, Beatty JW, et al. · J Med Chem 2026
- Discovery of Casdatifan, Part I: Design and Characterization of Tetrahydroquinoline Inhibitors of Hypoxia-Inducible Factor-2α.
Mata G, Mailyan AK, Drew SL, et al. · J Med Chem 2026
- Targeting HIF-2α in renal cell carcinoma: Expanding upon belzutifan.
Rodriguez M, Qin Q, Tambar UK, et al. · Cancer 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.